ReviewCurrent neuropharmacology2024
A Comprehensive Review on the Importance of MiRNA-206 in the Animal Model and Human Diseases.
Review in Current neuropharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Myogenic differentiation-derived small extracellular vesicles as a therapeutic strategy for miR-193b-3p-mediated muscle regeneration.Molecular therapy. Nucleic acids · 2026Article
- CircRNA HIPK2-mediated metabolic reprogramming restores mitochondrial homeostasis in chondrocytes through the miR-206/Sirt3 signaling axis attenuating osteoarthritis-induced nociception.Inflammopharmacology · 2026Article
- Article
- Integrating multimodal features to predict the malignancy of pulmonary ground-glass nodules: a multicenter prospective model development and validation study.Frontiers in oncology · 2025Article
- Mechanosensitive miRNAs in Cartilage and Subchondral Bone Remodeling: Emerging Targets for Osteoarthritis Therapy.Journal of inflammation research · 2025Review
- Evidence for the Contribution of the miR-206/BDNF Pathway in the Pathophysiology of Depression.The international journal of neuropsychopharmacology · 2024Review
- Perspective Strategies for Interventions in Parkinsonism: Remedying the Neglected Role of TPPP.Cells · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
MicroRNA-206 (miR-206) is a microRNA that is involved in many human diseases, such as myasthenia gravis, osteoarthritis, depression, cancers, etc. Both inhibition effects and progression roles of miR-206 have been reported for the past few years. High expression of miR-206 was observed in patients with osteoarthritis, gastric cancer and epithelial ovarian cancer compared to normal people. The study also showed that miR-206 promotes cancer progression in breast cancer patients and avascular necrosis of the femoral head. Meanwhile, several studies have shown that expression levels of miR-206 were down-regulated in laryngeal carcinoma cell multiplication, as well as in hepatocellular carcinoma, non-small lung cancer and infantile hemangioma. Moreover, miR-206 was up-regulated in the mild stage of amyotrophic lateral sclerosis patients and then down-regulated in the moderate and severe stages, indicating that miR-206 has the double effects of starting and aggravating the disease. In neuropsychiatric disorders, such as depression, miR-206 also plays an important role in the progression of the disease; the level of miR-206 is most highly expressed in the brains of patients with depression. In the current review, we summarize the role of miR-206 in various diseases, and miR-206 may be developed as a new biomarker for diagnosing diseases in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.